天目药业(600671.SH)：前三季度净利润1420.88万元

Core Insights - Tianmu Pharmaceutical (600671.SH) reported a total operating revenue of 159 million yuan for the first three quarters of 2025, representing a year-on-year increase of 27.48% [1] - The net profit attributable to shareholders of the parent company reached 14.21 million yuan, a significant turnaround from a loss of 3.70 million yuan in the same period last year [1] - The basic earnings per share stood at 0.1167 yuan [1]